Kallikrein 15 antibody (AA 78-106)
Quick Overview for Kallikrein 15 antibody (AA 78-106) (ABIN5536342)
Target
See all Kallikrein 15 (KLK15) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 78-106
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This KLK15 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 78-106 amino acids from the Central region of human KLK15.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5 mg/mL
-
Buffer
- Supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- Kallikrein 15 (KLK15) (Kallikrein-Related Peptidase 15 (KLK15))
-
Alternative Name
- KLK15
-
Background
- Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In prostate cancer, this gene has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer. The gene contains multiple polyadenylation sites and alternative splicing results in multiple transcript variants encoding distinct isoforms.
-
Molecular Weight
- 28 kDa
-
Gene ID
- 55554
-
UniProt
- Q9H2R5
-
Pathways
- Complement System
Target
-